Oncology

With a new dosing schedule, low toxicity and a PD-L1 expression-driven response was observed.

With the comment period ending today, the proposed CMS cuts to radiation oncology reimbursement rates might have a substantial impact on community treatment centers.

Data in study show removal of tobacco from stores led to surge in purchase of nicotine patches.

Cancer drug cost troubles in the UK prompt NHS to slash its list of approved-for-use oncology products.

For individuals who have not made the sort of risk-averse decisions in their lives that lead to better jobs and wealth accumulation, making treatment decisions after a cancer diagnosis can be very difficult, said Amy Davidoff, PhD, MS, senior research scientist in public health at the Yale School of Public Health

Urologists analyzing data from prostate cancer patients suggest wait and watch in well-informed low-risk prostate cancer patients.

A survey of groups using and developing clinical pathways revealed 7 distinct themes that highlight how these pathways are created and used, and the challenges and barriers to creating new pathways, explained Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council.

Study provides proof that a child's genetic makeup can provide actionable information to alter cancer treatment regimens.

Novartis has announced that Zarxio will be available at 15% of the cost of its reference product Neupogen.

Men are opting for preventive breast surgery when diagnosed with unilateral invasive disease, a study published in JAMA Surgery has found.

Personalized telephone counseling and tailored educational materials can improve colonoscopy rates among at-risk family members of patients with colorectal cancer.

Rolapitant was approved to prevent delayed phase chemotherapy-induced nausea and vomiting in adult patients.

The Cancer Prevention and Ethics Committees of the American Society of Clinical Oncology have made several recommendations that address genetic and genomic testing policies for cancer risk assessment.

Sometimes patients are so concerned with being good patients that they simply agree to what the clinician has said without fully understanding, and it's important to ask questions and ensure their voices are heard, said Mary Lou Smith, MBA, co-founder of the Research Advocacy Network.

The submission by BMS includes results from the ELOQUENT-2 trial that were recently published in the New England Journal of Medicine.

A novel microRNA gene signature could guide earlier intervention in pancreatic cancer.

An expert panel of ASCO developed recommendations for advanced lung cancer treatment after reviewing published literature.

The new guidance released by HRSA proposes to improve oversight over the drug pricing program.

Pharmacy cost trends are expected to increase 10% up from 6.3% the year before, with specialty pharmacy trends experiencing the largest increases, according to a survey from Aon Health.

The study published in JNCI has identified CES2 expression as a predictor of response to FOLFIRINOX.

While the shift to cancer becoming more of a chronic disease does not have a huge change on the approach of the payer, there are some new challenges to address, said Jennifer Malin, MD, medical director for oncology at Anthem.

Published in the journal Neurology, the study identified childhood cancer, along with hypertension and age, as a risk factor for recurrent stroke.

A pathways company has followed up its medical and radiation oncology clinical decision tools with a new surgical oncology platform.

The Biosimilars Council wants CMS to hold back on Medicare Part B reimbursement for biosimilars.

An article published in the Journal of Clinical Oncology finds that survivorship care plans may not greatly improve patient satisfaction with their care.